Alembic Pharmaceuticals receives approval for Teriflunomide tablets

Alembic Pharmaceuticals has received approval from the USFDA for its ANDA Teriflunomide tablets. 

Teriflunomide tablets, 7 mg and 14 mg is therapeutically equivalent to the reference listed drug Aubagio Tablets, 7 mg and 14 mg, of Sanofi-Aventis US, LLC Sanofi-Aventis. Teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis. 

According to IQVIA, Teriflunomide Tablets, 7 mg and 14 mg have an estimated market size of US$1.6 billion for 12 months ending December 2018. Alembic now has a total of 91 ANDA approvals (79 final approvals and 12 tentative approvals) from USFDA. 

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. 

On Thursday, the shares of Alembic Pharma opened at Rs. 551.35. At the closing bell, it was at Rs 545.90, down by 1.88 per cent. It reached an intraday high of Rs. 553.15 and an intraday low of Rs. 540 per share on the BSE. The 52-week high stood at Rs. 664 and 52-week low was at Rs. 412.40 per share on the BSE.